Ginkgo Bioworks Operating Income Over Time
| DNA Stock | USD 8.86 0.36 3.90% |
With this module, investors can use any or all of fundamental ratio historical patterns as a complementary method for asset selection as well as a tool for deciding entry and exit points. Many technical investors use fundamentals to limit their universe of possible portfolio assets.
Check out Ginkgo Bioworks Performance and Ginkgo Bioworks Correlation. Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Ginkgo Bioworks. Projected growth potential of Ginkgo fundamentally drives upward valuation adjustments. The financial industry is built on trying to define current growth potential and future valuation accurately. Comprehensive Ginkgo Bioworks assessment requires weighing all these inputs, though not all factors influence outcomes equally.
Earnings Share (6.18) | Revenue Per Share | Quarterly Revenue Growth (0.56) | Return On Assets | Return On Equity |
Understanding Ginkgo Bioworks Holdings requires distinguishing between market price and book value, where the latter reflects Ginkgo's accounting equity. The concept of intrinsic value - what Ginkgo Bioworks' is actually worth based on fundamentals - guides informed investors toward better entry and exit points. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Market sentiment, economic cycles, and investor behavior can push Ginkgo Bioworks' price substantially above or below its fundamental value.
It's important to distinguish between Ginkgo Bioworks' intrinsic value and market price, which are calculated using different methodologies. Investment decisions regarding Ginkgo Bioworks should consider multiple factors including financial performance, growth metrics, competitive position, and professional analysis. In contrast, Ginkgo Bioworks' trading price reflects the actual exchange value where willing buyers and sellers reach mutual agreement.
Cross Equities Operating Income Analysis
Compare Ginkgo Bioworks Holdings and related stocks such as Iovance Biotherapeutics, Replimune Group, and MBX Biosciences Common Operating Income Over Time
Select Fundamental| 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| IOVA | (57.1 K) | (21.2 M) | (8.1 M) | (22.6 M) | (12 M) | (27.9 M) | (53.6 M) | (92.9 M) | (128.3 M) | (206.9 M) | (261.9 M) | (342.7 M) | (398.9 M) | (460.6 M) | (395.3 M) | (355.8 M) | (338 M) |
| REPL | (9.6 M) | (9.6 M) | (9.6 M) | (9.6 M) | (9.6 M) | (9.6 M) | (9.6 M) | (19.2 M) | (30.9 M) | (56.2 M) | (82.8 M) | (121.5 M) | (177.1 M) | (234.8 M) | (261.6 M) | (235.5 M) | (223.7 M) |
| MBX | (25.2 M) | (25.2 M) | (25.2 M) | (25.2 M) | (25.2 M) | (25.2 M) | (25.2 M) | (25.2 M) | (25.2 M) | (25.2 M) | (25.2 M) | (25.2 M) | (25.2 M) | (35.3 M) | (68.2 M) | (61.4 M) | (64.4 M) |
| MGTX | (20.1 M) | (20.1 M) | (20.1 M) | (20.1 M) | (20.1 M) | (20.1 M) | (20.1 M) | (31.7 M) | (78.1 M) | (58.3 M) | (62.6 M) | (72.8 M) | (116.4 M) | (137.1 M) | (164.2 M) | (147.8 M) | (140.4 M) |
| AVBP | (8.7 M) | (8.7 M) | (8.7 M) | (8.7 M) | (8.7 M) | (8.7 M) | (8.7 M) | (8.7 M) | (8.7 M) | (8.7 M) | (8.7 M) | (36.9 M) | (74.6 M) | (94.3 M) | (94.3 M) | (84.9 M) | (89.1 M) |
| MRVI | 16.4 M | 16.4 M | 16.4 M | 16.4 M | 16.4 M | 16.4 M | 16.4 M | 16.4 M | 16.4 M | 24 M | 119.9 M | 554.6 M | 574.2 M | (31.6 M) | (235.6 M) | (212.1 M) | (201.5 M) |
| ATXS | (15.7 K) | (15.7 K) | (15.7 K) | (18.1 M) | (21.7 M) | (31.7 M) | (35.6 M) | (27.1 M) | (26.4 M) | (27.1 M) | (37.4 M) | (195 M) | (53.5 M) | (83 M) | (111.6 M) | (100.4 M) | (95.4 M) |
| VIR | (81.5 M) | (81.5 M) | (81.5 M) | (81.5 M) | (81.5 M) | (81.5 M) | (81.5 M) | (81.5 M) | (118.7 M) | (178 M) | (297 M) | 420.8 M | 833.1 M | (684.3 M) | (587.2 M) | (479.3 M) | (455.4 M) |
| ARVN | (16.5 M) | (16.5 M) | (16.5 M) | (16.5 M) | (16.5 M) | (16.5 M) | (16.5 M) | (24.8 M) | (43.8 M) | (51.5 M) | (124.9 M) | (195.3 M) | (263.2 M) | (401.5 M) | (250.2 M) | (225.2 M) | (236.4 M) |
| VALN | (1.4 M) | (4.5 M) | (12.8 M) | (20.9 M) | (23.8 M) | (19.9 M) | (42.6 M) | (4 M) | 6.3 M | (811 K) | (55.1 M) | (61.4 M) | (113.4 M) | (82.1 M) | 13.3 M | 12 M | 12.6 M |
Ginkgo Bioworks Holdings and related stocks such as Iovance Biotherapeutics, Replimune Group, and MBX Biosciences Common Operating Income description
Operating Income is the amount of profit realized from Ginkgo Bioworks Holdings operations after accounting for operating expenses such as cost of goods sold (COGS), wages and depreciation. Operating income takes the gross income and subtracts other operating expenses and then removes depreciation. Operating Income of Ginkgo Bioworks Holdings is typically a synonym for earnings before interest and taxes (EBIT) and is also commonly referred to as operating profit or recurring profit. Earnings before interest and taxes (EBIT), representing the amount of profit a company generates from its operations.My Equities
My Current Equities and Potential Positions
| Ginkgo Bioworks Holdings | DNA |
Specialization | Health Care, Pharmaceuticals, Biotechnology & Life Sciences |
| Business Address | 27 Drydock Avenue, |
| Exchange | New York Stock Exchange |
USD 8.86
Check out Ginkgo Bioworks Performance and Ginkgo Bioworks Correlation. You can also try the Equity Analysis module to research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities.
Ginkgo Bioworks technical stock analysis exercises models and trading practices based on price and volume transformations, such as the moving averages, relative strength index, regressions, price and return correlations, business cycles, stock market cycles, or different charting patterns.